The hantavirus survival rate is one of the most searched — and most misunderstood — statistics in infectious disease. The honest answer is that it depends heavily on which virus strain, where treatment happens, and how early the patient reaches intensive care. For some strains, survival odds are over 99%. For Andes hantavirus, the primary strain in the 2026 MV Hondius outbreak, roughly 60% of patients survive.
Case Fatality Rates by Strain
The wide variation in outcomes across hantavirus strains is one of the most striking features of this viral family:
| Strain | Disease | CFR (approximate) | Primary Region |
|---|---|---|---|
| Sin Nombre | HPS | 35–38% | USA / Canada |
| Andes | HPS | 35–40% | Argentina / Chile |
| Juquitiba / Araraquara | HPS | 40–50% | Brazil |
| Laguna Negra | HPS | 15–25% | Bolivia / Paraguay |
| Puumala | HFRS (Nephropathia Epidemica) | < 1% | Europe / Scandinavia |
| Hantaan | HFRS (severe) | 5–15% | Korea / China |
| Seoul | HFRS (mild) | < 1% | Worldwide (rats) |
| Dobrava | HFRS (variable) | 5–12% | Balkans |
The MV Hondius cluster involved Andes hantavirus. Of the 16 confirmed cases as of May 18, 3 have died — a case fatality rate of 18.75% within this group. However, several cases remain in active ICU care, meaning the final CFR may change.
Why Does the Cardiopulmonary Phase Kill?
Hantavirus Pulmonary Syndrome (HPS) kills through a single mechanism: non-cardiogenic pulmonary edema. The virus infects pulmonary capillary endothelial cells, causing massive fluid leak into the alveoli. The lungs fill with fluid faster than they can clear it.
What makes this so dangerous:
- Speed: A patient who walked into an ER with fever can be in respiratory failure within 24–48 hours
- Atypical presentation: Early symptoms (fever, myalgia, headache) are indistinguishable from flu or COVID. Most patients are not identified as potential HPS until they begin deteriorating
- No specific antiviral: There is no approved antiviral therapy proven effective for HPS. Treatment is supportive — oxygen, mechanical ventilation, vasopressors for shock, ECMO in severe cases
What Actually Saves Lives: The ICU Data
Multiple retrospective studies show that survival in HPS is strongly predicted by early ICU transfer and hemodynamic support before cardiac collapse.
Key findings from published data:
- Patients transferred to ICU before developing cardiogenic shock had a survival rate of approximately 62–68% in large Andean case series
- Patients who required ECMO (extracorporeal membrane oxygenation) had outcomes varying from 30% to 55% survival depending on the center
- Patients at centers with no ECMO capability and late transfer showed CFRs approaching 60–70%
In the MV Hondius cluster, at least three patients required ECMO support. The availability of this technology in European centers (Netherlands, France, Germany) is significantly higher than in rural South American settings where most Andes cases historically occur — which may partly explain why Hondius CFR appears lower than baseline Andes endemic data.
Factors That Predict Better Survival
Younger age: HPS mortality increases significantly with age. Patients over 60 have roughly double the CFR of patients under 40 in most series.
No underlying cardiovascular disease: The cardiopulmonary phase stresses cardiac output maximally. Pre-existing heart disease dramatically worsens prognosis.
Earlier hospital presentation: Patients who present during the prodrome (fever, myalgia) rather than during respiratory failure have more time for monitoring and intervention.
Hospital setting: Tertiary-level hospitals with ECMO capability, 24-hour intensivists, and experience with high-acuity viral pneumonitis have meaningfully better outcomes than community hospitals.
Female sex (possible protective effect): Some studies suggest women have slightly better HPS survival than men, potentially due to hormonal differences in endothelial permeability regulation. The data is not yet conclusive.
Who Does NOT Recover: Risk Patterns
The patients least likely to survive:
- Delayed presentation (arrived in respiratory distress rather than early fever)
- Rapid bilateral pulmonary infiltrates on admission chest X-ray
- Hematocrit > 45% (hemoconcentration indicating severe capillary leak)
- Low platelet count (thrombocytopenia < 100,000/μL on admission)
- Cardiac index < 2.5 L/min/m² early in the cardiopulmonary phase
- Rural areas without ICU access or ECMO capability
Can Survivors Have Long-Term Effects?
Yes. HPS survivors frequently report:
- Persistent dyspnea (shortness of breath) for months to years
- Reduced exercise tolerance
- Fatigue and neurocognitive complaints (“brain fog”)
- Pulmonary function abnormalities on spirometry
Full recovery to baseline is common among younger patients but less certain in older survivors or those who required prolonged mechanical ventilation. Data on long-term outcomes for Hondius patients is not yet available, as most are still in the acute or early recovery phase.
The Hondius Outcomes So Far
As of May 18, 2026:
- 16 confirmed cases total
- 3 confirmed deaths
- At least 4 patients discharged following ICU care
- Several patients remain hospitalised, some in ICU
- Outcomes for recently confirmed cases (Netherlands 16th, Italy 15th) are too early to report
The Hondius cluster is, in many ways, a case study in how European ICU infrastructure performs against a virus that has historically been a developing-world disease. The data, when complete, will inform future preparedness planning.
Track live case counts and country-by-country outcomes → Hantavirus Map
Explore HantavirusMap